U.K.-based short-acting psychedelics developer Small Pharma Inc. (OTCQB: DMTTF) has been working hard on securing a proprietary IP throughout North America, Australasia and Europe.

CEO George Tziras says the team has made progress in 2023 to further strengthen the company’s IP position in key international markets by building multi-layered IP protection around each pipeline program and thus helping optimize their commercial potential.

“We are pleased that our efforts to invest in developing novel treatment innovations for patients continues to be recognized in multiple jurisdictions,” Tziras added.

The company’s protection strategy includes the discovery of novel drugs and their therapeutic compositions …

Full story available on Benzinga.com

A note to our visitors

This website has updated its privacy policy in compliance with changes to European Union data protection law, for all members globally. We’ve also updated our Privacy Policy to give you more information about your rights and responsibilities with respect to your privacy and personal information. Please read this to review the updates about which cookies we use and what information we collect on our site. By continuing to use this site, you are agreeing to our updated privacy policy.